Literature DB >> 9141206

Venezuelan equine encephalitis virus vaccines induce mucosal IgA responses and protection from airborne infection in BALB/c, but not C3H/HeN mice.

M K Hart1, W Pratt, F Panelo, R Tammariello, M Dertzbaugh.   

Abstract

Immunization with either a live-attenuated (TC-83) or formalin-inactivated (C-84) vaccine for Venezuelan equine encephalitis (VEE) virus protected BALB/c mice from lethal VEE infection acquired subcutaneously or by aerosol. While vaccinated C3H/HeN mice were also protected from parenteral infection, neither vaccine protected these mice from an aerosol infection. The apparent vaccine failures in C3H/HeN mice could not be attributed to deficiencies in virus-neutralizing antibodies in serum, as these responses were typically of equal or higher titer than those observed in protected BALB/c mice before challenge. IgG subclass analysis offered no facile explanation: profiles of IgG2 alpha dominance were observed in C3H/HeN mice given either vaccine and in BALB/c mice given the live-attenuated vaccine, whereas BALB/c antibody responses shifted toward IgGl dominance after immunization with the killed C-84 vaccine. Data from immunized congenic mice showed that the H-2 genes from the C3H/He mice were not singularly responsible for the inability of these mice to resist aerosol infection with VEE virus. VEE virus-specific IgA responses were detected more frequently in respiratory and vaginal secretions obtained from the protected BALB/c mice.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9141206     DOI: 10.1016/s0264-410x(96)00204-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  21 in total

1.  Antibody to the E3 glycoprotein protects mice against lethal venezuelan equine encephalitis virus infection.

Authors:  Michael D Parker; Marilyn J Buckley; Vanessa R Melanson; Pamela J Glass; David Norwood; Mary Kate Hart
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Rapid, non-invasive imaging of alphaviral brain infection: reducing animal numbers and morbidity to identify efficacy of potential vaccines and antivirals.

Authors:  Michael Patterson; Allison Poussard; Katherine Taylor; Alexey Seregin; Jeanon Smith; Bi-Hung Peng; Aida Walker; Jenna Linde; Jennifer Smith; Milagros Salazar; Slobodan Paessler
Journal:  Vaccine       Date:  2011-10-12       Impact factor: 3.641

3.  Treatment of Venezuelan equine encephalitis virus infection with (-)-carbodine.

Authors:  Justin G Julander; Richard A Bowen; Jagadeeshwar R Rao; Craig Day; Kristiina Shafer; Donald F Smee; John D Morrey; Chung K Chu
Journal:  Antiviral Res       Date:  2008-08-15       Impact factor: 5.970

4.  Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles.

Authors:  Patrick R Harrington; Boyd Yount; Robert E Johnston; Nancy Davis; Christine Moe; Ralph S Baric
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

5.  Self-Amplifying RNA Vaccines for Venezuelan Equine Encephalitis Virus Induce Robust Protective Immunogenicity in Mice.

Authors:  Marcelo M Samsa; Lesley C Dupuy; Clayton W Beard; Carolyn M Six; Connie S Schmaljohn; Peter W Mason; Andrew J Geall; Jeffrey B Ulmer; Dong Yu
Journal:  Mol Ther       Date:  2019-01-07       Impact factor: 11.454

6.  A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates.

Authors:  Lesley C Dupuy; Michelle J Richards; Barry Ellefsen; Lillian Chau; Alain Luxembourg; Drew Hannaman; Brian D Livingston; Connie S Schmaljohn
Journal:  Clin Vaccine Immunol       Date:  2011-03-30

7.  Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus.

Authors:  Shannon S Martin; Russell R Bakken; Cathleen M Lind; Patricia Garcia; Erin Jenkins; Pamela J Glass; Michael D Parker; Mary Kate Hart; Donald L Fine
Journal:  Vaccine       Date:  2010-03-01       Impact factor: 3.641

8.  Telemetric analysis to detect febrile responses in mice following vaccination with a live-attenuated virus vaccine.

Authors:  Shannon S Martin; Russell R Bakken; Cathleen M Lind; Douglas S Reed; Jessica L Price; Craig A Koeller; Michael D Parker; Mary Kate Hart; Donald L Fine
Journal:  Vaccine       Date:  2009-09-15       Impact factor: 3.641

9.  C3H/HeN mouse model for the evaluation of antiviral agents for the treatment of Venezuelan equine encephalitis virus infection.

Authors:  Justin G Julander; Ramona Skirpstunas; Venkatraman Siddharthan; Kristiina Shafer; Justin D Hoopes; Donald F Smee; John D Morrey
Journal:  Antiviral Res       Date:  2008-02-13       Impact factor: 5.970

10.  Acute infection with venezuelan equine encephalitis virus replicon particles catalyzes a systemic antiviral state and protects from lethal virus challenge.

Authors:  Jennifer L Konopka; Joseph M Thompson; Alan C Whitmore; Drue L Webb; Robert E Johnston
Journal:  J Virol       Date:  2009-09-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.